Suven [SUVENPHAR] vs Eris Lifesciences [ERIS] Detailed Stock Comparison
Suven
NSE
Loading...
Eris Lifesciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Suven wins in 8 metrics, Eris Lifesciences wins in 11 metrics, with 0 ties. Eris Lifesciences appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Suven | Eris Lifesciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 99.01 | 61.28 | Eris Lifesciences |
| Price-to-Book Ratio | 13.88 | 8.31 | Eris Lifesciences |
| Debt-to-Equity Ratio | 1.95 | 75.74 | Suven |
| PEG Ratio | -9.13 | 1.47 | Suven |
| EV/EBITDA | 72.65 | 24.67 | Eris Lifesciences |
| Profit Margin (TTM) | 26.63% | 13.17% | Suven |
| Operating Margin (TTM) | 31.70% | 26.73% | Suven |
| EBITDA Margin (TTM) | 31.70% | 26.73% | Suven |
| Return on Equity | 14.38% | 10.75% | Suven |
| Return on Assets (TTM) | 8.73% | 5.00% | Suven |
| Free Cash Flow (TTM) | $1.32B | $9.10B | Eris Lifesciences |
| Dividend Yield | N/A | 0.41% | N/A |
| 1-Year Return | 32.02% | 38.68% | Eris Lifesciences |
| Price-to-Sales Ratio (TTM) | 39.38 | 8.09 | Eris Lifesciences |
| Enterprise Value | $266.01B | $263.97B | Suven |
| EV/Revenue Ratio | 25.37 | 8.99 | Eris Lifesciences |
| Gross Profit Margin (TTM) | 66.67% | 76.07% | Eris Lifesciences |
| Revenue per Share (TTM) | $41 | $216 | Eris Lifesciences |
| Earnings per Share (Diluted) | $10.90 | $28.41 | Eris Lifesciences |
| Beta (Stock Volatility) | 1.13 | -0.03 | Eris Lifesciences |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Suven vs Eris Lifesciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Suven | -1.24% | 6.42% | 7.30% | -9.89% | 0.96% | -3.49% |
| Eris Lifesciences | 0.98% | 3.98% | -0.96% | 16.32% | 36.93% | 31.57% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Suven | 32.02% | 132.38% | 270.69% | 643.80% | 643.80% | 643.80% |
| Eris Lifesciences | 38.68% | 153.19% | 238.28% | 191.21% | 191.21% | 191.21% |
Performance & Financial Health Analysis: Suven vs Eris Lifesciences
| Metric | SUVENPHAR | ERIS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹412.87B | ₹237.39B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 270,601 | 159,048 |
| 90 Day Avg. Volume | 308,763 | 117,654 |
| Last Close | ₹1,083.35 | ₹1,768.70 |
| 52 Week Range | ₹815.05 - ₹1,360.00 | ₹1,097.20 - ₹1,910.00 |
| % from 52W High | -20.34% | -7.40% |
| All-Time High | ₹1,360.00 (Dec 02, 2024) | ₹1,910.00 (Jun 09, 2025) |
| % from All-Time High | -20.34% | -7.40% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.40% | 0.08% |
| Quarterly Earnings Growth | 0.77% | 0.42% |
| Financial Health | ||
| Profit Margin (TTM) | 0.27% | 0.13% |
| Operating Margin (TTM) | 0.32% | 0.27% |
| Return on Equity (TTM) | 0.14% | 0.11% |
| Debt to Equity (MRQ) | 1.95 | 75.74 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹77.73 | ₹209.63 |
| Cash per Share (MRQ) | ₹25.80 | ₹15.09 |
| Operating Cash Flow (TTM) | ₹2.95B | ₹7.57B |
| Levered Free Cash Flow (TTM) | ₹2.65B | ₹3.52B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.41% |
| Last 12-Month Dividend | ₹0.00 | ₹7.35 |
Valuation & Enterprise Metrics Analysis: Suven vs Eris Lifesciences
| Metric | SUVENPHAR | ERIS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 99.01 | 61.28 |
| Forward P/E | 57.20 | 41.80 |
| PEG Ratio | -9.13 | 1.47 |
| Price to Sales (TTM) | 39.38 | 8.09 |
| Price to Book (MRQ) | 13.88 | 8.31 |
| Market Capitalization | ||
| Market Capitalization | ₹412.87B | ₹237.39B |
| Enterprise Value | ₹266.01B | ₹263.97B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 25.37 | 8.99 |
| Enterprise to EBITDA | 72.65 | 24.67 |
| Risk & Other Metrics | ||
| Beta | 1.13 | -0.03 |
| Book Value per Share (MRQ) | ₹77.73 | ₹209.63 |
Financial Statements Comparison: Suven vs Eris Lifesciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SUVENPHAR | ERIS |
|---|---|---|
| Revenue/Sales | ₹4.02B | ₹7.72B |
| Cost of Goods Sold | ₹1.34B | ₹1.85B |
| Gross Profit | ₹2.68B | ₹5.87B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹467.80M | ₹2.06B |
| EBITDA | ₹841.30M | ₹2.80B |
| Pre-Tax Income | ₹516.00M | ₹1.61B |
| Income Tax | ₹128.70M | ₹360.00M |
| Net Income (Profit) | ₹387.30M | ₹1.25B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SUVENPHAR | ERIS |
|---|---|---|
| Cash & Equivalents | ₹854.00M | ₹2.00B |
| Total Current Assets | ₹8.89B | ₹12.23B |
| Total Current Liabilities | ₹3.65B | ₹13.81B |
| Long-Term Debt | ₹1.76B | ₹17.82B |
| Total Shareholders Equity | ₹18.41B | ₹32.72B |
| Retained Earnings | N/A | ₹27.93B |
| Property, Plant & Equipment | ₹9.95B | ₹2.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SUVENPHAR | ERIS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SUVENPHAR | ERIS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 270,601 | 159,048 |
| Average Daily Volume (90 Day) | 308,763 | 117,654 |
| Shares Outstanding | 254.56M | 136.16M |
| Float Shares | 101.32M | 40.85M |
| % Held by Insiders | 0.73% | 0.69% |
| % Held by Institutions | 0.15% | 0.21% |
Dividend Analysis & Yield Comparison: Suven vs Eris Lifesciences
| Metric | SUVENPHAR | ERIS |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹7.35 |
| Last 12-Month Dividend Yield | N/A | 0.41% |
| 3-Year Avg Annual Dividend | ₹0.33 | ₹4.90 |
| 3-Year Avg Dividend Yield | 0.22% | 0.82% |
| 3-Year Total Dividends | ₹1.00 | ₹14.70 |
| Ex-Dividend Date | Sep 09, 2022 | Feb 13, 2025 |